Companies press releases
08 Jan, 2024, 10:33 ET Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Data Readout on Track for 1Q Calendar Year 2024 Topline Results […]
20 Dec, 2023, 07:30 ET Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin’s focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J., Dec. 20, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million Read More »
18 Dec, 2023, 16:15 ET CRANBURY, N.J., Dec. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the “Exchange”) approving Palatin’s plan (the
14 Nov, 2023, 07:30 ET Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024 Topline Results Currently Expected in
09 Nov, 2023, 07:30 ET CRANBURY, N.J., Nov. 9, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its
24 Oct, 2023, 16:50 ET CRANBURY, N.J., Oct. 24, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of
Palatin Announces Closing of $5 Million Registered Direct Offering Read More »
23 Oct, 2023, 07:30 ET CRANBURY, N.J., Oct. 23, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for
Palatin Announces $5 Million Registered Direct Offering Read More »
19 Oct, 2023, 07:30 ET 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter last year $2.1 million in Net Product Revenue 18% growth over prior quarter; 137% growth over comparable quarter last year Prescriptions Dispensed
18 Oct, 2023, 07:30 ET Positive data with Palatin’s melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data shows increased weight loss and greater glucose control above monotherapy Preclinical data and prior clinical studies support the further clinical development and commercial potential of
16 Oct, 2023, 07:30 ET Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J., Oct. 16, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system,
